Sanofi Stock Other OTC
Stocks
SNYNF
FR0000120578
Pharmaceuticals
OTC Markets Traded| Market Cap | 91.4B 104B 85.08B 78.14B 147B 9,970B 149B 1,011B 395B 4,923B 390B 382B 17,016B | P/E 2026 * |
11.4x | P/E 2027 * | 10.5x |
|---|---|---|---|---|---|
| Enterprise Value | 101B 115B 94.21B 86.52B 162B 11,040B 165B 1,120B 437B 5,451B 432B 423B 18,841B | EV / Sales 2026 * |
2.15x | EV / Sales 2027 * | 1.94x |
| Free-Float |
89% | Yield 2026 * |
5.6% | Yield 2027 * | 5.92% |
Last Transcript: Sanofi
| 1 day | -1.88% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 57 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 64 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.88% | -.--% | - | - | 104B | |
| +0.16% | +4.29% | +48.02% | +162.90% | 1,067B | |
| +1.76% | +7.61% | +61.09% | +54.16% | 635B | |
| -0.16% | +2.08% | +37.19% | +73.76% | 458B | |
| +1.41% | +8.56% | +38.18% | +32.17% | 347B | |
| +1.28% | +4.40% | +37.69% | +41.62% | 295B | |
| +1.72% | +4.10% | +19.44% | +20.45% | 262B | |
| +1.84% | -0.46% | -27.63% | -38.65% | 216B | |
| +0.22% | +3.29% | +24.85% | +59.35% | 203B | |
| +1.64% | -1.53% | +16.05% | +71.44% | 161B | |
| Average | +0.91% | +1.33% | +28.32% | +53.02% | 404.83B | |
| Weighted average by Cap. | +0.89% | +1.95% | +37.92% | +78.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.15B 53.64B 43.89B 40.31B 75.69B 5,144B 76.69B 522B 204B 2,540B 201B 197B 8,779B | 50.34B 57.26B 46.86B 43.03B 80.8B 5,491B 81.87B 557B 218B 2,711B 215B 210B 9,371B |
| Net income | 8.44B 9.6B 7.85B 7.21B 13.54B 920B 13.72B 93.35B 36.46B 454B 36.03B 35.25B 1,571B | 9.44B 10.73B 8.78B 8.07B 15.15B 1,029B 15.35B 104B 40.78B 508B 40.3B 39.43B 1,757B |
| Net Debt | 9.8B 11.15B 9.13B 8.38B 15.74B 1,069B 15.94B 108B 42.36B 528B 41.86B 40.96B 1,825B | 6.15B 6.99B 5.72B 5.25B 9.86B 670B 9.99B 67.99B 26.56B 331B 26.24B 25.67B 1,144B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
